GPR49 protein is an important marker for the identification and targeted intervention of liver cancer tumor-initiating cells.

Author: Senior Product Manager of UA Views：10

GPR49, also known as LGR5, is a Wnt signaling pathway-related receptor and an important marker of tumor-initiating cells and cancer stem cells in various tumors.

Recent Advances
Product Information

Recent Advances

GPR49 Protein Is an Important Marker for the Identification and Targeted Intervention of Liver Cancer Tumor-Initiating Cells

Brief Introduction: GPR49, also known as LGR5, is a Wnt signaling pathway-related receptor and an important marker of tumor-initiating cells and cancer stem cells in multiple tumors. A 2020 study published in Nature Communications showed that LGR5-positive cells are enriched in mouse liver cancer models and human hepatocellular carcinoma, possess stronger organoid-forming and tumor-initiating abilities, and exhibit resistance to conventional treatments such as sorafenib and 5-FU; diphtheria toxin-mediated LGR5 lineage ablation can inhibit tumor growth, and combining it with 5-FU can further enhance efficacy. Structural characterization, antibody screening, receptor binding, and cross-species cross-reactivity evaluation around GPR49 protein can provide key support for liver cancer stem cell research and targeted drug development.

I. GPR49 protein is a G protein-coupled receptor rich in leucine-rich repeats.

GPR49, namely LGR5, also known as GPR67, is a member of the class A rhodopsin-like GPCR family. The human LGR5 gene is located on chromosome 12q22-23, and the protein consists of 907 amino acids. Its extracellular region contains 17 leucine-rich repeats, with N-terminal and C-terminal flanks rich in cysteine and multiple glycosylation sites; the transmembrane region is composed of 7 highly conserved α-helices. These structural features enable it to participate in ligand recognition, receptor complex assembly, and downstream signal transduction. In normal liver homeostasis, LGR5-positive cells are usually scarce or absent, but they can be induced during tissue injury, inflammatory stimulation, or tumorigenesis.

II. GPR49 protein regulates Wnt signaling output through its R-spondin receptor function.

LGR5 is a high-affinity receptor for R-spondin family proteins and can cooperate with Frizzled and LRP5/6 to enhance Wnt/β-catenin signaling. Its mechanism mainly involves the LGR5/R-spondin complex binding to and internalizing the transmembrane E3 ligases RNF43 and ZNRF3, thereby reducing ubiquitination-mediated degradation of Wnt receptors, increasing the abundance of Wnt receptors on the cell surface, and amplifying Wnt signaling output. During liver tumorigenesis, LGR5-positive cells are often accompanied by Wnt pathway activation and are associated with enhanced expression of tumor stemness-related genes. Some studies also suggest that LGR5 may have more complex regulatory roles in different tumor types and microenvironments, which need to be verified in specific models.

III. GPR49 protein is enriched in liver cancer and marks tumor-initiating cells.

Studies have found that a stable LGR5-positive cell population can appear in DEN-induced mouse liver cancer models, and its abundance is significantly higher than in surrounding tumor tissue or chemically injured liver. After flow cytometric sorting, LGR5-positive cells show a clear advantage in in vitro organoid formation assays, and the organoid formation rate from single cells is significantly higher than that of LGR5-negative cells. In vivo transplantation experiments also show that LGR5-positive cells have stronger tumor-initiating ability. In human hepatocellular carcinoma cohorts, LGR5 expression is significantly elevated compared with paired tumor-free liver tissue, and patients with high expression have a worse prognosis.

IV. GPR49 protein-positive cells are resistant to conventional therapy and can be enriched.

Studies further found that LGR5-positive liver cancer cells exhibit strong resistance to conventional treatments such as sorafenib and 5-FU. After sorafenib treatment of tumor organoids, the proportion of LGR5-positive cells increased; after 5-FU treatment, this effect was even more pronounced. After in vivo transplanted tumors were treated with sorafenib or 5-FU, the proportion of LGR5-positive cells in the tumors also increased. Even when organoids were re-cultured from LGR5-negative cells and treated again with 5-FU, the cultures were still dominated by LGR5-positive cells. These results indicate that conventional anticancer therapy may, under selective pressure, relatively enrich LGR5-positive tumor-initiating cells, thereby becoming an important source of recurrence and drug resistance.

V. GPR49 protein lineage ablation can inhibit organoid formation and tumor growth.

Diphtheria toxin-mediated LGR5 lineage ablation experiments showed that eliminating LGR5-positive cells can significantly inhibit the growth and formation of tumor organoids, and the inhibitory effect is closely related to the reduction in the number of LGR5-positive cells. In in vivo models, simply eliminating LGR5-positive cells in already formed tumors had limited effect on tumor volume; however, early LGR5 lineage ablation after tumor organoid transplantation could significantly delay tumor onset and inhibit tumor growth. This result suggests that LGR5-positive cells may play a more critical role in tumor initiation and early expansion stages, and targeting this cell population may help weaken the tumor's sustained growth capacity.

VI. GPR49 protein targeting combined with 5-FU can enhance anti-liver cancer efficacy.

The study also evaluated the potential of combining LGR5 lineage ablation with conventional drug therapy. The combination of diphtheria toxin and sorafenib did not significantly enhance the antitumor activity against transplanted tumors; however, the combination of diphtheria toxin and 5-FU was clearly superior to monotherapy and showed certain efficacy in both simultaneous and sequential administration strategies. This finding suggests that intervention targeting LGR5-positive tumor-initiating cells may complement conventional chemotherapy: chemotherapeutic drugs mainly act on rapidly proliferating tumor cells, while LGR5-targeted elimination may weaken the cell population with tumor-initiating and drug-resistant potential, thereby improving overall therapeutic efficacy.

VII. GPR49 protein recombinant reagents are important tools for cross-species research and drug evaluation.

In antibody screening, receptor binding assays, flow cytometry detection, SPR/BLI interaction evaluation, and organoid model establishment, GPR49 recombinant protein can be used to verify antibody specificity, evaluate binding activity, establish positive cell detection methods, and support target validation. Because LGR5-targeted drug development involves human tumor models and non-human primate preclinical evaluation, selecting recombinant proteins from different species such as human, mouse, and cynomolgus monkey helps carry out cross-species cross-reactivity studies and preclinical safety assessment. Cynomolgus monkeys have high translational value in the immune system, metabolic pathways, and drug evaluation, and their LGR5/GPR49 recombinant protein can be used for antibody cross-reactivity validation and biomarker method establishment.

Conclusion

In response to the research needs of the GPR49/LGR5 target and the application of recombinant proteins, UniArt provides LGR5/GPR49 His Tag Protein, Cynomolgus. This product can be used for cross-reactivity evaluation of cynomolgus-derived LGR5 antibodies, receptor binding activity detection, flow cytometry binding validation, support for non-human primate preclinical research, and target validation in liver cancer stem cell marker detection and targeted drug development. By providing stable and reliable recombinant protein tools, UniArt can provide technical support for LGR5/GPR49-related basic research and translational research.

As an important marker of liver cancer tumor-initiating cells, GPR49 protein not only helps understand the mechanisms of tumorigenesis, drug resistance, and recurrence, but also provides a basis for targeted therapy and combination treatment strategies. With the improvement of recombinant proteins, antibody screening, and cross-species evaluation tools, GPR49/LGR5-related research is expected to further support liver cancer stem cell biology and preclinical development of targeted drugs.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next